{"groups":[{"description":"MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A.\n\nDexamethasone: Given PO\n\nIxazomib: Given PO","id":"FG000","title":"Arm B (Ixazomib and Dexamethasone)"},{"description":"MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A and lenalidomide PO daily on days 1-21.\n\nDexamethasone: Given PO\n\nIxazomib: Given PO\n\nLenalidomide: Given PO","id":"FG001","title":"Arm C (Ixazomib, Dexamethasone, Lenalidomide)"},{"description":"UNMUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone.\n\nDexamethasone: Given PO\n\nIxazomib: Given PO","id":"FG002","title":"Arm A (Ixazomib and Dexamethasone)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"21"},{"groupId":"FG002","numSubjects":"27"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"21"},{"groupId":"FG002","numSubjects":"27"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}